Overview
The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients:
- Baricitinib treatment for 12 months
- Biologics treatment for 12 months
- Tofacitinib treatment for 12 months
Eligibility
Inclusion Criteria:
- RA patients
Exclusion Criteria:
- Not RA patients
- RA patients who are allergic to the drugs, refused to do this research, or who are pregnant